Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage

被引:28
作者
Cameron, Jamie [1 ]
Holla, Oystein L. [1 ]
Laerdahl, Jon K. [2 ]
Kulseth, Mari Ann [1 ]
Berge, Knut Erik [1 ]
Leren, Trond P. [1 ]
机构
[1] Rikshosp Univ Hosp, Med Genet Lab, Dept Med Genet, N-0027 Oslo, Norway
[2] Rikshosp Univ Hosp, Inst Med Microbiol, CMBN, NO-0027 Oslo, Norway
关键词
Cholesterol; LDL receptor; Mutation; PCSK9; LDL RECEPTOR; IDENTIFICATION; DECREASES;
D O I
10.1016/j.atherosclerosis.2008.10.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The normal function of proprotein convertase subtilisin/kexin type 9 (PCSK9) is to mediate degradation of the low density lipoprotein (LDL) receptors. However, the exact mechanism for this function remains to be determined. Characterization of how the naturally occurring mutations in the PCSK9 gene affect the function of PCSK9, may provide important insight into the mechanism by which PCSK9 degrades the LDL receptors. Methods: DNA sequencing of the 12 exons with flanking intron sequences of the PCSK9 gene was performed in 1336 unrelated hypercholesterolemic subjects. In vitro assays and bioinformatics analysis were employed to characterize the functional consequences of a novel mutation. Experimental results: One subject was heterozygous for the novel mutation S462P in exon 9 of the PCSK9 gene. Based upon Western blot analysis of transiently transfected HepG2 cells, S462P-PCSK9 was almost completely retained in the endoplasmic reticulum (ER) even though it did undergo autocatalytic cleavage. Thus, only trace amounts of S462P-PCSK9 were detected in the culture media of transfected cells. Flow cytometric experiments revealed that the S462P-PCSK9 mutant was unable to degrade the LDL receptors. Discussion: The markedly reduced secretion of S462P-PCSK9 makes S462P a loss-of-function mutation. Ser462 is one of the few residues in the C-terminal domain which is conserved in all known PCSK9 homologs. A hydrogen bond between the side-chain of Ser462 and the backbone of beta-strand 6 of the C-terminal domain, appears to be essential for the proper folding of the C-terminal domain. The S462P mutation is believed to disrupt the normal folding of the C-terminal domain leading to retention of the mutant protein in the ER. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 165
页数:5
相关论文
共 25 条
[1]   Mutations in PCSK9 cause autosomal dominant hypercholesterolemia [J].
Abifadel, M ;
Varret, M ;
Rabès, JP ;
Allard, D ;
Ouguerram, K ;
Devillers, M ;
Cruaud, C ;
Benjannet, S ;
Wickham, L ;
Erlich, D ;
Derré, A ;
Villéger, L ;
Farnier, M ;
Beucler, I ;
Bruckert, E ;
Chambaz, J ;
Chanu, B ;
Lecerf, JM ;
Luc, G ;
Moulin, P ;
Weissenbach, J ;
Prat, A ;
Krempf, M ;
Junien, C ;
Seidah, NG ;
Boileau, C .
NATURE GENETICS, 2003, 34 (02) :154-156
[2]   NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol [J].
Benjannet, S ;
Rhainds, D ;
Essalmani, R ;
Mayne, J ;
Wickham, L ;
Jin, WJ ;
Asselin, MC ;
Hamelin, J ;
Varret, M ;
Allard, D ;
Trillard, M ;
Abifadel, M ;
Tebon, A ;
Attie, AD ;
Rader, DJ ;
Boileau, C ;
Brissette, L ;
Chrétien, M ;
Prat, A ;
Seidah, NG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (47) :48865-48875
[3]   The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A-Functional consequences of natural mutations and post-translational modifications [J].
Benjannet, Suzanne ;
Rhainds, David ;
Hamelin, Josee ;
Nassoury, Nasha ;
Seidah, Nabil G. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (41) :30561-30572
[4]   Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy [J].
Berge, KE ;
Ose, L ;
Leren, TP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) :1094-1100
[5]   Characterization of novel mutations in the catalytic domain of the PCSK9 gene [J].
Cameron, J. ;
Holla, O. L. ;
Laerdahl, J. K. ;
Kulseth, M. A. ;
Ranheim, T. ;
Rognes, T. ;
Berge, K. E. ;
Leren, T. P. .
JOURNAL OF INTERNAL MEDICINE, 2008, 263 (04) :420-431
[6]   Effect of mutations in the PCSK9 gene on the cell surface LDL receptors [J].
Cameron, J ;
Holla, OL ;
Ranheim, T ;
Kulseth, MA ;
Berge, KE ;
Leren, TP .
HUMAN MOLECULAR GENETICS, 2006, 15 (09) :1551-1558
[7]   Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion [J].
Cameron, Jamie ;
Holla, Oystein L. ;
Berge, Knut Erik ;
Kulseth, Mari Ann ;
Ranheim, Trine ;
Leren, Trond P. ;
Laerdahl, Jon K. .
FEBS JOURNAL, 2008, 275 (16) :4121-4133
[8]   Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia [J].
Cunningham, David ;
Danley, Dennis E. ;
Geoghegan, Kieran F. ;
Griffor, Matthew C. ;
Hawkins, Julie L. ;
Subashi, Timothy A. ;
Varghese, Alison H. ;
Ammirati, Mark J. ;
Culp, Jeffrey S. ;
Hoth, Lise R. ;
Mansour, Mahmoud N. ;
McGrath, Katherine M. ;
Seddon, Andrew P. ;
Shenolikar, Shirish ;
Stutzman-Engwall, Kim J. ;
Warren, Laurie C. ;
Xia, Donghui ;
Qiu, Xiayang .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (05) :413-419
[9]  
DeLano WL., 2002, PYMOL MOL GRAPHICS S
[10]   The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain [J].
Hampton, Eric N. ;
Knuth, Mark W. ;
Li, Jun ;
Harris, Jennifer L. ;
Lesley, Scott A. ;
Spraggon, Glen .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (37) :14604-14609